MedTrace Logo

A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors

NCT06239155 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 51

Last updated 2025-02-25

No results posted yet for this study

Summary

An open-label, Phase I/II study to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of AST-3424 administered as a single agent

Conditions

Interventions

DRUG

AST-3424

liquid formulation for Intravenous infusion

Sponsors & Collaborators

  • Ascentawits Pharmaceuticals, Ltd

    lead INDUSTRY

Principal Investigators

  • Jin Li · Shanghai East Hospital

  • Shukui Qin · Chinese People's Liberation Army Eastern Theater General Hospital Qinhuai medical District

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-09-03
Primary Completion
2025-11-30
Completion
2025-11-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06239155 on ClinicalTrials.gov